ICM
TEVA icon

IMS Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

IMS Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-190
Closed -$4K – 324
2018
Q3 		$4K Buy
+190
New +$4.41K ﹤0.01% 363
2014
Q4 		– Sell
-4,100
Closed -$220K – 166
2014
Q3 		$220K Hold
4,100
– – 0.26% 137
2014
Q2 		$215K Hold
4,100
– – 0.23% 140
2014
Q1 		$217K Buy
+4,100
New +$189K 0.26% 127

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

IMS Capital Management's TEVA Position: Q4 2018 in Review

IMS Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2018, closing a stake of 190 shares — an estimated $4K sold.

IMS Capital Management first reported a position in TEVA in Q1 2014 and held it in 4 quarters. The position peaked at $220K in Q3 2014. 551 funds tracked by Wall St. Rank hold TEVA as of Q4 2018.

  • IMS Capital Management reported no remaining Teva Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • IMS Capital Management sold 190 Teva Pharmaceuticals shares in Q4 2018, an estimated $4K.
  • IMS Capital Management first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 4 quarters.
  • IMS Capital Management's Teva Pharmaceuticals position peaked at $220K in Q3 2014.
  • 551 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2018.

Based on IMS Capital Management's 13F filing for Q4 2018, filed 7 Feb 2019.